PDF(Pubmed)
Abstract：
UNASSIGNED: The transcription factor, SOX13 is part of the SOX family. SOX proteins are crucial in the progression of many cancers, and some correlate with carcinogenesis. Nonetheless, the biological and clinical implications of SOX13 in human breast cancer (BC) remain rarely known.
UNASSIGNED: We evaluated the survival and expression data of SOX13 in BC patients via the UNLCAL, GEPIA, TIMER, and Kaplan-Meier plotter databases. Immunohistochemistry (IHC) was used to verify clinical specimens. The gene alteration rates of SOX13 were acquired on the online web cBioportal. With the aid of the TCGA data, the association between SOX13 mRNA expression and copy number alterations (CNA) and methylation was determined. LinkedOmics was used to identify the genes that co-expressed with SOX13 and the regulators. Immune infiltration and tumor microenvironment evaluations were assessed by ImmuCellAI and TIMER2.0 databases. SOX13 correlated drug resistance analysis was performed using the GDSC2 database.
UNASSIGNED: Higher SOX13 expression was discovered in BC tissues in comparison to normal tissues. Moreover, increased gene mutation and amplification of SOX13 were found in BC. Patients with increased SOX13 expression levels showed worse overall survival (OS). Cox analysis showed that SOX13 independently served as a prognostic indicator for poor survival in BC. Further, the expression of SOX13 was also confirmed to be correlated with tumor microenvironment and diverse infiltration of immune cells. In terms of drug sensitivity analysis, we found higher expression level of SOX13 predicts a high IC50 value for most of 198 drugs which predicts drug resistance.
UNASSIGNED: The present findings demonstrated that high expression of SOX13 negatively relates to prognosis and SOX13 plays an important role in cancer immunity. Therefore, SOX13 may potentially be adopted as a biomarker for predicting BC prognosis and infiltration of immune cells.
UNASSIGNED: We evaluated the survival and expression data of SOX13 in BC patients via the UNLCAL, GEPIA, TIMER, and Kaplan-Meier plotter databases. Immunohistochemistry (IHC) was used to verify clinical specimens. The gene alteration rates of SOX13 were acquired on the online web cBioportal. With the aid of the TCGA data, the association between SOX13 mRNA expression and copy number alterations (CNA) and methylation was determined. LinkedOmics was used to identify the genes that co-expressed with SOX13 and the regulators. Immune infiltration and tumor microenvironment evaluations were assessed by ImmuCellAI and TIMER2.0 databases. SOX13 correlated drug resistance analysis was performed using the GDSC2 database.
UNASSIGNED: Higher SOX13 expression was discovered in BC tissues in comparison to normal tissues. Moreover, increased gene mutation and amplification of SOX13 were found in BC. Patients with increased SOX13 expression levels showed worse overall survival (OS). Cox analysis showed that SOX13 independently served as a prognostic indicator for poor survival in BC. Further, the expression of SOX13 was also confirmed to be correlated with tumor microenvironment and diverse infiltration of immune cells. In terms of drug sensitivity analysis, we found higher expression level of SOX13 predicts a high IC50 value for most of 198 drugs which predicts drug resistance.
UNASSIGNED: The present findings demonstrated that high expression of SOX13 negatively relates to prognosis and SOX13 plays an important role in cancer immunity. Therefore, SOX13 may potentially be adopted as a biomarker for predicting BC prognosis and infiltration of immune cells.
摘要：
■转录因子，SOX13是SOX家族的一部分。SOX蛋白在许多癌症的进展中至关重要，有些与致癌作用有关。尽管如此，SOX13在人类乳腺癌（BC）中的生物学和临床意义仍然鲜为人知。
■我们通过UNLCAL评估了BC患者中SOX13的生存和表达数据，GEPIA,TIMER,和Kaplan-Meier绘图仪数据库。免疫组织化学(IHC)用于验证临床标本。SOX13的基因变异率是在在线网站cBioportal上获得的。借助TCGA数据,确定SOX13mRNA表达与拷贝数改变(CNA)和甲基化之间的关联.LinkedOmics用于鉴定与SOX13和调节因子共表达的基因。通过ImmuCellAI和TIMER2.0数据库评估免疫浸润和肿瘤微环境评估。使用GDSC2数据库进行SOX13相关耐药性分析。
■与正常组织相比,在BC组织中发现了更高的SOX13表达。此外，在BC中发现SOX13的基因突变和扩增增加。具有增加的SOX13表达水平的患者显示更差的总体存活(OS)。Cox分析显示，SOX13独立地作为BC生存不良的预后指标。Further,SOX13的表达也被证实与肿瘤微环境和免疫细胞的不同浸润有关。在药物敏感性分析方面，我们发现,在198种预测耐药的药物中,SOX13的表达水平越高,IC50值越高.
■本研究结果表明，SOX13的高表达与预后呈负相关，SOX13在癌症免疫中起重要作用。因此,SOX13可能被用作预测BC预后和免疫细胞浸润的生物标志物。
■我们通过UNLCAL评估了BC患者中SOX13的生存和表达数据，GEPIA,TIMER,和Kaplan-Meier绘图仪数据库。免疫组织化学(IHC)用于验证临床标本。SOX13的基因变异率是在在线网站cBioportal上获得的。借助TCGA数据,确定SOX13mRNA表达与拷贝数改变(CNA)和甲基化之间的关联.LinkedOmics用于鉴定与SOX13和调节因子共表达的基因。通过ImmuCellAI和TIMER2.0数据库评估免疫浸润和肿瘤微环境评估。使用GDSC2数据库进行SOX13相关耐药性分析。
■与正常组织相比,在BC组织中发现了更高的SOX13表达。此外，在BC中发现SOX13的基因突变和扩增增加。具有增加的SOX13表达水平的患者显示更差的总体存活(OS)。Cox分析显示，SOX13独立地作为BC生存不良的预后指标。Further,SOX13的表达也被证实与肿瘤微环境和免疫细胞的不同浸润有关。在药物敏感性分析方面，我们发现,在198种预测耐药的药物中,SOX13的表达水平越高,IC50值越高.
■本研究结果表明，SOX13的高表达与预后呈负相关，SOX13在癌症免疫中起重要作用。因此,SOX13可能被用作预测BC预后和免疫细胞浸润的生物标志物。
